Femasys, Inc. FEMY 深 滬
已收盤 04-02 16:00:00 美东时间
0.4392
+0.022
+5.32%
華盛通- 最 高0.4485
- 今 開0.4166
- 成交量 27.41万股
- 最 低 0.4086
- 昨 收 0.417
- 總市值 2613.32万
- 52周最高 1.29
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 0.3067
- 委 比 -65.75%
- 總股本 5950.19万
- 歷史最高 13.75
- 量 比 0.24
- 振 幅 9.57%
- 歷史最低 0.2479
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Femasys Appoints John Canning COO
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of
04-01 21:03
Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 47.83 percent. This is a 73.91 percent increase over losses of $(0.23) per share from the same
04-01 05:10
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5
Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $1.5.
03-04 01:59
Femasys Secures American Medical Association CPT Editorial Panel Approval For Category III CPT Code Covering Use Of FemaSeed For Intratubal Insemination
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making
02-23 22:10
Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution
02-03 22:16
Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health
01-13 22:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
Femasys Receives 510(k) Clearance From FDA For FemVue Controlled Device, Diagnostic Solution For Controlled Contrast Delivery To Evaluate Fallopian Tube Status
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency--ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc.
2025-12-18 22:16
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
